Prophylactic or Pre-emptive Therapies to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Int J Hematol

Specialty Hematology

Date 2023 Jul 7

PMID 37418118

Authors

Shinichi Kako

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic stem cell transplantation is a potent curative treatment for hematological malignancies, but relapse is still a major problem. Donor lymphocyte infusion (DLI) and maintenance therapies after transplantation are promising strategies to reduce the risk of relapse. DLI augments the graft-versus-tumor effect by directly adding allo-reactive donor lymphocytes, and has been used in relapsed patients. In this Progress in Hematology (PIH), we will focus on prophylactic or pre-emptive DLI, including DLI from a haploidentical donor. On the other hand, specific drugs, which are used in maintenance therapies for each disease, kill tumor cells directly and/or immunologically by stimulating immune cells. Maintenance therapies should be started early after transplantation without severe myelosuppression. Molecularly targeted drugs are therefore suitable for use in maintenance therapies, and are reviewed in this PIH. The optimal application of these strategies has not yet been established. However, important evidence regarding their efficacies, adverse events, and effects on immune systems is accumulating, and could help to improve outcomes in allogeneic transplantation.

References

Childs R, Srinivasan R . Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J. 2002; 8(1):2-11. DOI: 10.1097/00130404-200201000-00002. View

Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y . Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004; 18(5):1013-9. DOI: 10.1038/sj.leu.2403343. View

Gyurkocza B, Sandmaier B . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124(3):344-53. PMC: 4102707. DOI: 10.1182/blood-2014-02-514778. View

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J . Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51(11):1431-1438. DOI: 10.1038/bmt.2016.167. View

Stein A, Kantarjian H, Gokbuget N, Bargou R, Litzow M, Rambaldi A . Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(8):1498-1504. DOI: 10.1016/j.bbmt.2019.04.010. View

Gao X, Lin J, Wang S, Huang W, Li F, Li H . Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. Ann Hematol. 2018; 98(1):185-193. PMC: 6334751. DOI: 10.1007/s00277-018-3482-7. View

Barrett A, Savani B . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006; 20(10):1661-72. DOI: 10.1038/sj.leu.2404334. View

Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76(12):2462-5. View

10.

Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y . Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for.... Biol Blood Marrow Transplant. 2014; 20(11):1785-90. DOI: 10.1016/j.bbmt.2014.07.010. View

11.

Schmid C, de Wreede L, van Biezen A, Finke J, Ehninger G, Ganser A . Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European.... Haematologica. 2017; 103(2):237-245. PMC: 5792268. DOI: 10.3324/haematol.2017.168716. View

12.

Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M . Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012; 26(6):1211-7. DOI: 10.1038/leu.2011.351. View

13.

Bar M, Sandmaier B, Inamoto Y, Bruno B, Hari P, Chauncey T . Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013; 19(6):949-57. PMC: 3846289. DOI: 10.1016/j.bbmt.2013.03.001. View

14.

Stemler J, de Jonge N, Skoetz N, Sinko J, Bruggemann R, Busca A . Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022; 9(5):e361-e373. DOI: 10.1016/S2352-3026(22)00073-4. View

15.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

16.

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

17.

Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View

18.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

19.

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

20.

Cortes J, Khaled S, Martinelli G, Perl A, Ganguly S, Russell N . Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019; 20(7):984-997. DOI: 10.1016/S1470-2045(19)30150-0. View